Abbvie Inc. vs Repligen Corp
ABBV vs RGEN — side-by-side comparison from reported financials. ABBV leads 9, RGEN leads 1 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
| Metric | ABBV | RGEN |
|---|---|---|
| Price | $276.43 | $173.88 |
| Market cap | $488B | $11.0B |
| Revenue (TTM) | $64.4B | $785M |
| Revenue growth | +1.8% | -2.7% |
| Net margin | 9.8% | 5.3% |
| Free cash flow | $18.2B | $112M |
| Net cash (debt) | ($56.2B) | $225M |
| 1-year price return | +19.8% | +16.8% |
| P/E | 77.4 | 265.8 |
| P/E vs own history (cheap-side %) | 23% | 2% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 2% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 7 of 11 |
| Employees | 57,000 | 2,000 |
Full résumé-style profiles: ABBV CV · RGEN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.